PharmaEssentia has launched BESREMi (ropeginterferon alfa-2b) in Singapore, the first market in Southeast Asia to offer this innovative treatment for Polycythaemia Vera (PV), a rare blood cancer.
PharmaEssentia
Approved by Singapore’s Health Sciences Authority, BESREMi targets the disease at its source for long-term control and reduced risk of progression.
With around 500 PV patients in Singapore, this launch aims to improve outcomes and raise awareness about the importance of early detection and treatment of PV, especially in conjunction with MPN Awareness Day.
BESREMi®️ provides an innovative solution that targets directly the source of the disease for long-term control to reduce the risk of disease progression and thrombosis, says Dr. Peggy Loh, Singapore General Manager at PharmaEssentia.
